NRSN

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NRSN

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/20	22 : 00	PR Newswire (US)	NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/05/14	22 : 05	PR Newswire (US)	NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/05/07	21 : 45	PR Newswire (US)	NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/05/02	22 : 19	PR Newswire (US)	NeuroSense Announces First Quarter 2024 Business Update	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/04/22	21 : 30	PR Newswire (US)	NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/04/18	21 : 30	PR Newswire (US)	NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/04/12	21 : 30	PR Newswire (US)	NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/04/11	08 : 16	PR Newswire (US)	NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/04/09	21 : 30	PR Newswire (US)	NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/04/05	22 : 29	PR Newswire (US)	NeuroSense Announces Year End 2023 Financial Results and Provides Business Update	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/02/22	22 : 25	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/02/22	22 : 25	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/02/21	22 : 30	PR Newswire (US)	NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/02/14	03 : 20	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/02/14	00 : 14	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/02/07	23 : 38	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/02/07	23 : 27	PR Newswire (US)	NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/01/09	22 : 49	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/01/09	22 : 48	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2024/01/09	22 : 45	PR Newswire (US)	NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/28	07 : 03	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/28	07 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/28	07 : 00	PR Newswire (US)	NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/21	22 : 45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/15	06 : 30	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/14	23 : 41	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/14	23 : 24	PR Newswire (US)	NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/06	05 : 15	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/06	05 : 00	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd
2023/12/05	22 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NRSN	NeuroSense Therapeutics Ltd